Will GSK achieve 8% core EPS growth in its February 3 annual results?

Question

This market will resolve YES if GSK reports full-year 2026 Core earnings-per-share growth of at least 8.0% at constant exchange rates, according to its official results scheduled for February 3, 2027. A result that does not meet the specified numerical condition resolves NO. The date identifies the scheduled publication, while the accounting period named in the condition remains fixed if the announcement moves.

Use the Core EPS growth percentage in the constant-exchange-rate column, labelled CE

Problyx · Accepted Answer

Yes — the community forecast puts this at 53%.

Problyx · Answer

No — the community forecast puts this at 47%.